Novo - SELECT Trial - 10 Points to Consider (BUY, TP DKK1300)
Wegovy’s SELECT has just read out positively with a much better than expected 20% MACE risk reduction in Overweight or Obese patients with CV disease. This has a number of implications and we believe there is considerable upside to consensus forecasts for Novo and all other GLP-1 compounds.For access to the full comment and to discuss these results, please contact Naresh Chouhan ( )
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.